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The development of chemotherapy for seminoma has tended 
to follow the principles determined for the management of non-
seminoma, a more common clinical indication (Einhorn and
Williams, 1980). Variations of a combination of cisplatin, etoposide
and bleomycin (BEP) have become standard treatment, not only for
patients with disseminated seminoma or recurrence after radio-
therapy, but also for those who present with metastatic disease
confined to the retroperitoneal nodes but which measures more than
5 cm in transverse diameter (Horwich and Dearnaley, 1992; Mencel
et al, 1994; Fosså and Horwich, 1997). The role of bleomycin in the
treatment of seminoma with these drug combinations is uncertain,
firstly, in view of the poor results of treatment with the combination
of vinblastine and bleomycin (Samuels et al, 1976) and secondly, in
view of the demonstrated efficacy of combinations such as etopo-
side plus cisplatin (Mencel et al, 1994) or cyclophosphamide plus
cisplatin (Logothetis et al, 1987). Furthermore, a number of reports
emphasize the sensitivity of seminoma to single agent cisplatin or
carboplatin suggesting that these approaches lead to similar disease
control to that achieved by combination chemotherapy but with
reduced toxicity (Samuels and Logothetis, 1983; Horwich et al,
1989; Oliver, 1988; Dieckmann et al, 1990; Schmoll et al, 1991).
The UK Medical Research Council therefore launched a prospective
randomized trial in 1990 to compare single agent carboplatin (C)
with the combination of etoposide and cisplatin (EP) in patients with
advanced metastatic seminoma. 
PATIENTS AND METHODS 
Eligibility and study entry 
Chemo-naive patients with histologically confirmed testicular or
extragonadal seminoma, glomerular filtration rate ≥ 40 ml min–1, and
AFP <25 ku l–1, who had either relapsed with any stage of disease
following previous irradiation, or were newly diagnosed with Royal
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agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated
with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent
carboplatin (C) at a dose of 400 mg/m2 to be corrected for glomerular filtration rate outside the range 81–120 ml min–1 and to be administered
on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to
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target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized
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survival was 0.85 with 95% CI, 0.35–2.10, log rank chi-squared = 0.12, P = 0.73. The trial has not demonstrated statistically significant
differences in the major survival endpoints comparing single agent carboplatin with a combination of etoposide + cisplatin. This cannot be
taken as an indication of equivalence since the limited size of this trial rendered it unable to exclude a 19% lower progression-free survival and
survival in those treated with single agent carboplatin which would be important clinically. Standard initial chemotherapy for advanced
seminoma should be based on cisplatin combinations and the role of carboplatin awaits the outcome of further studies. © 2000 Cancer
Research Campaign http://www.bjcancer.com
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1979). Patients were randomized by telephone call to the MRC
Cancer Trials Office, and allocated either 4 cycles of etoposide and
cisplatin (EP) or 4 cycles of single agent carboplatin (C). Treatment
was allocated by minimization balanced by centre and stage. 
EP schedule and dose modifications 
For patients allocated EP, the recommended schedule was pre-
hydration of 1 l N-saline plus 20 mmol KCl six-hourly × 2; after
which cisplatin at 20 mg/m2 was given in 1 l N-saline + 20 mmol
KCl over 6 hours, followed by 1 l N-saline + 20 mmol KCl 6
hourly × 3. Cisplatin was given at this dose on days 1, 2, 3, 4 and 5
of each cycle. Etoposide was given at 120 mg/m2 as a 1 hour infu-
sion in 250 ml N-saline on days 1, 2 and 3. Four cycles of EP were
given at 21-day intervals. 
Dose modifications for etoposide were based on full blood
counts on day 1 of the cycle to be administered. Full doses were
given only if WBC was >2 × 109 l–1 and platelets >90 × 109 l–1. 
If WBC was <1 × 109 l–1 or platelets were <50 × 109 l–1,
chemotherapy was delayed for 4 days and recommenced with 50%
etoposide when WBC and platelets had risen. For blood counts
between these levels, or for nadir WBC <1.5 × 109 l–1 or nadir
platelets <50 × 109 l–1, etoposide dose was reduced by 25%. If
glomerular filtration rate (GFR) measured by clearance of creat-
inine or EDTA fell below 40 ml min–1, cisplatin was discontinued
and treatment with carboplatin recommended. 
Carboplatin schedule and dose modifications 
For patients allocated carboplatin, a single dose was given over 60
minutes in 500 ml 5% dextrose on day 1 of each cycle. Four cycles
were given at 21-day intervals. The initial dose of carboplatin was
based on Glomerular Filtration Rate (GFR) estimated by clearance
of Chromium-51 labelled EDTA, and surface area, as follows
(If GFR was estimated by creatinine clearance the carboplatin
dose in this table was reduced by 10%.) 
EDTA GFR Carboplatin dose (mg/m2) 
>140 460 
121–140 440 
81–120 400 
61–80 350 
41–60 300 
26–40 200 
<25 100 
Blood counts were measured weekly during chemotherapy. Dose
modifications for subsequent carboplatin were based on nadir
blood counts; the dose was escalated by 10% if nadir WBC was
>3 × 109 l–1 and platelets >150 × 109 l–1, and reduced by 10% if
WBC was <1.5 × 109 l–1 or platelets <50 × 109 l–1. However if, on
day 1 of the cycle to be administered, WBC was <2 × 109 l–1, or
platelets <100 × 109 l–1 the course was delayed and blood counts
reassessed every 3 days until they exceeded these levels.
Treatment of residual masses 
The protocol recommended that residual masses greater than 5 cm
were biopsied and if tumour-negative, followed up with CT scans
at 6 and 12 months, and annually thereafter, unless complete
regression occurred. Masses less than 5 cm in diameter were
followed by CT scanning at 3 monthly intervals for the 1st year,
and considered for biopsy if no regression had occurred after 6
months. Patients with a tumour-negative biopsy had a further CT
at 12 months and then annually. A tumour-positive biopsy at any
time was recorded as a treatment failure, with subsequent treat-
ment left to clinical discretion. In practice only 3 of the 10 patients
who had residual masses over 5 cm in size were biopsied; the
remainder were followed as for smaller masses. 
Following recurrence, patients were re-staged with serum
marker assays and CT of thorax and abdomen. Treatment was left
to clinical discretion, but with cisplatin-based regimens being re-
commended for carboplatin relapses, and consideration given to
the possibility of radiotherapy consolidation. 
Statistical considerations 
The primary endpoint of the study was progression-free survival
(PFS) at 3 years. The enlargement of existing masses, appearance of
new metastases, tumour-positive biopsy at any time and death from
tumour or treatment were considered as events in the PFS analysis.
Three-year PFS after EP was expected to be approximately 80%, and
the trial was designed as an equivalence study, aiming to exclude 
a reduction in the 3-year PFS in patients allocated carboplatin of
between 10 and 15%. The initial study target was 250 patients, suffi-
cient to exclude a 15% difference (90% power, significance level 
(1-sided) 5%), with continuation to 550 (sufficient to exclude a 10%
difference) dependent upon the Data Monitoring Committee (DMC)
recommendation at that time. Secondary endpoints included failure-
free survival in which death from any cause, as well as those events
described for PFS were included, overall survival, acute toxicity 
and an optional assessment of long-term ototoxicity and fertility. All
event-free rates and confidence intervals on 3-year survival rates
were calculated using the Kaplan–Meier method, and compared
using the log-rank test. The event hazard ratios and their 95% confi-
dence intervals were estimated using Cox’s proportional hazards
regression model; hazard ratios less than one indicate a benefit to the
etoposide/cisplatin combination. 
RESULTS 
Accrual and patient characteristics 
The study opened in August 1990, and by November 1993, 125
patients had been randomized. At this time, the independent DMC
met to review the interim results. Accrual had declined consider-
ably in the previous 6 months following presentation of trial re-
sults confirming the inferiority of carboplatin-based therapy over
cisplatin-based chemotherapy for metastatic non-seminoma. The
DMC recommended that the trial be closed in view of the poor
recent accrual and the interim results which, though not con-
ventionally significant, showed similar trends to the results of
randomized trials in metastatic non-seminoma (Bajorin et al,
1993; Horwich et al, 1997) and non-randomized studies in
metastatic seminoma (C-13 events, EP 7 events, Hazard Ratio 0.45
log-rank, P = 0.08). Events were failures or early death. The trial
was closed formally early in 1994, when 130 patients had been
randomized from 18 centres in the UK, 5 in the Netherlands and 
1 in Norway. 64 patients were allocated C, and 66 EP. We report
here long-term follow-up of these patients. 
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balanced between the treatment groups. 18 patients (14%) had
relapsed following previous radiotherapy. Of the remainder, 75
had stage IIC disease, 29 stage III and 8 stage IV. The primary
tumour site was the testis in 85% of patients. Age at study entry
ranged from 18 to 70 years with a median of 38. 
Treatment details 
Of 64 patients allocated C, treatment information is missing on 4
patients. Of the remaining 60, 56 received all 4 cycles and in 26 of
these patients at least one dose escalation was possible. 3 patients
changed treatment before 4 cycles had been completed because of
lack of response, including one patient in whom the diagnosis was
later changed to malignant thymoma. Finally, one patient received
BEP throughout (clinical decision). 
Of 66 patients allocated EP, treatment information is missing on
2. Of the remaining 64, 62 received all 4 EP cycles, with 10 of
these 62 patients requiring at least one dose reduction of etoposide
because of haematological toxicity, and one requiring a 50% re-
duction in cycles 3 and 4 cisplatin because of renal and ototoxicity.
One patient received carboplatin rather than cisplatin in cycles 3
and 4 because of renal toxicity, and one patient died after 2 cycles
from a pulmonary embolism which was possibly treatment 
related. 
The maximum toxicity grade over all chemotherapy cycles is
given in Table 2. WBC was significantly lower in patients alloc-
ated EP (chi-square (trend) P < 0.001) with 20 (32%) EP patients
having grade 3 neutropenia compared with 2 (3%) of those 
allocated C. Platelets were statistically significantly lower in C
patients (chi-square (trend) P = 0.02), but grade 3 or 4 toxicity
occurred in only 5 patients in each group. Three patients allocated
Carboplatin chemotherapy in advanced seminoma 1625
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Table 1 Pre-treatment patient characteristics 
Treatment Allocated 
Carboplatin EP 
No. % No. % 
Relapse after No 55 85.9 57 86.4 
radiotherapy Yes 9 14.1 9 13.6 
Site of primary Testis 53 84.1 57 86.4 
Mediastinium 3 4.8 3 4.5 
Abdomen 4 6.3 5 7.5 
Other 3 4.8 1 1.5 
HCG (IU/1) at entry <10 49 76.6 39 60.9 
11–200 15 23.4 25 39.1 
Not known – – 2 – 
Abdominal nodes None 15 23.8 11 17.5 
(max diameter in cm) <2 1 1.5 1 1.6 
2–5 6 9.5 8 12.7 
5–10 28 44.4 33 52.4 
>10 13 20.6 10 15.9 
Not known 1 – 1 – 
Mediastinal nodes None 46 76.7 50 78.1 
(max diameter in cm) <2 3 4.7 
2–5 8 13.3 4 6.3 
5–10 3 5.0 4 6.3 
>10 3 5.0 3 4.7 
Not known 4 – 2 – 
Neck nodes None 53 82.8 61 93.8 
(max diameter in cm) <2 1 1.6
2–5 8 12.5 4 6.2 
5–10 2 3.1
Not known – – 1 – 
Lung metastases None 59 93.7 61 93.8 
(number) 1–4 4 6.3 3 4.6 
>=10 1 1.5 
Not known 1 1 – 
(max diameter in cm) None 59 93.7 61 95.3 
0.1–1.0 2 3.2 1 1.6 
1.1–2.0 1 1.6 1 1.6 
2.1–3.0 1 1.6
>3.0 1 1.6 
Not known 1 – 2 – 
Liver metastases NO 64 100.0 66 100.0 
Bone metastases NO 62 98.4 64 97.0 
YES 1 1.6 2 3.0 
Not known 1 – – – 
Brain metastases NO 63 98.4 66 100.0 
YES 1 1.6
Total 64 100.0 66 100.0 C and 10 allocated EP had grade ≥ 1 WHO grade diarrhoea, while
grade 3 or 4 nausea and vomiting was seen in 6 C patients and 
10 EP patients. Neurotoxicity was assessed immediately after
completion of chemotherapy in 29 C patients, none of whom 
experienced any WHO grade 1 or greater toxicity, and 38 EP 
patients 4 of whom had grade 1 and one grade 2. None of the 27 C
patients assessed at the completion of chemotherapy had WHO
grade 1 or more ototoxicity, but 6 EP patients did, with 4 going on
to have high tone hearing loss (8 kHz) confirmed by audiometry.
As expected, the number of in-patient days during initial chemo-
therapy was fewer in patients allocated C, with a median across all
cycles of 3 days (range 0–12), while for EP the median was 20
days (range 10–30). 
Response 
Of patients allocated C, 46 patients had a total of 59 residual
masses (median diameter 2.5 cm, range 0.5 to 13.8 cm), the
majority (39 patients) in the abdominal nodes. Two of these
abdominal masses were biopsied immediately after chemotherapy
(tumour-free) and 2 others were irradiated. Of patients allocated
EP, 50 patients had a total of 57 residual masses the majority (42)
again being the abdominal nodes (median diameter 2.5 cm, range
0.5 to 6 cm). One patient had resection of inguinal masses 
which were tumour-free, and 1 had biopsy of an abdominal mass
revealing seminoma. 3 were residual masses in the testis; orchid-
ectomy revealed no tumour. 3 of the 42 abdominal masses were
irradiated soon after chemotherapy. The final response assessment
(after any surgery or radiotherapy) is given in Table 3, 
in which patients with residual nodal masses less than 2 cm in
diameter are reported as having complete response (according to
the definitions used at the time). 
Follow-up and events 
Median follow-up time is now 4     years. 19 patients have died,
and of the survivors, 98 (81%) have been followed-up for at least 3
years. A total of 22 events (failures) have occurred among patients
allocated carboplatin; 12 patients progressed but are currently
alive and free from active disease, 9 after salvage chemotherapy
and 3 after radiotherapy. Seven have died from germ cell tumour
(GCT) following progression despite salvage chemotherapy, one
has died with the cause unknown (presumed to be GCT) and 2
have died from other causes without progression (one from misdi-
agnosed malignant thymoma, one from bronchopneumonia and
multiple infarct dementia). Thus a total of 19 patients have had
progression or death from GCT and are included in the progres-
sion-free survival analysis, and 10 have died and are included in
the overall survival analysis. 
A total of 14 events (failures) have occurred among patients
allocated EP. 5 patients are currently alive following successful
treatment of progression (3 after chemotherapy, 2 after radio-
therapy); 8 have died from GCT following progression despite
salvage chemotherapy, and one died while on treatment from a
pulmonary embolism and heart failure which was possibly treat-
ment related. All 14 events have been included in the progression-
free survival analysis, and the 9 deaths are included in the 
all-cause survival analysis. 
The progression-free survival (PFS) curves are shown in Figure 1.
The hazard ratio of 0.64, 95% CI (0.32, 1.28) favours the EP
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Table 2 Maximum haematological toxicity 
Treatment allocated 
Carboplatin EP
N % N % 
Thrombocytopenia Grade 0 33 56.9 53 85.5 
Grade 1 11 19.0 2 3.2 
Grade 2 9 15.5 2 3.2 
Grade 3 4 6.9 5 8.1 
Grade 4 1 1.7
Neutropenia Grade 0 16 27.6 3 4.8 
Grade 1 17 29.3 15 24.2 
Grade 2 23 39.7 24 38.7 
Grade 3 2 3.4 20 32.3 
Total 58 100.0 62 100.0 
N = Number of patients. 
Table 3 Chemotherapy response evaluation 
Treatment Allocated 
Carboplatin EP
N % N % 
Chemotherapy response Complete response 21 32.8  20 30.3 
Partial response 38 59.4 43 65.2 
No response 1 1.6 1 1.5 
Progressive disease 3 4.7 1 1.5 
Not evaluable 1 1.6 1 1.5 
N = Number of patients. 
1
2group, but the difference is not statistically significant (log-rank χ 2
= 1.59, P = 0.21). The estimated PFS rate at 3 years is 71%, 95%
CI (60%, 82%) in patients allocated C and 81%, 95% CI (71%,
90%) in those allocated EP, the 95% CI for the difference in 3-year
PFS being (– 6%, +19%). 
For failure-free survival (FFS) the hazard ratio again favours the
EP arm being 0.56, 95% CI (0.28, 1.09), log-rank χ 2 = 3.02, 
P = 0.08. The estimated FFS at 3 years is 67%, 95% CI (55%,
78%) in those allocated C and 81%, 95% CI (71%, 90%) in those
allocated EP. Thus the difference in 3-year FFS is 14% with 95%
CI (–2%, +22%). 
Overall survival curves are given in Figure 2. The hazard ratio 
is 0.85, with a broad 95% CI (0.35, 2.10), log-rank χ 2 = 0.12, 
P = 0.73. The 3-year survival rate is 84% (75%, 92%) in those
allocated C and 89% (81%, 96%) in those allocated EP. The esti-
mated difference in 3-year survival is therefore 5% in favour of EP,
but with a 95% CI (–20%, +10%). 
DISCUSSION 
A pilot study of single agent carboplatin chemotherapy for
advanced seminoma was based on 70 patients treated between
1982 and 1990 at the Royal Marsden (Horwich et al, 1989). This
documented the low toxicity of this approach and no patients
suffered neurotoxicity, ototoxicity or significant renal damage.
There was only one episode of neutropenic sepsis and no thrombo-
cytopenic bleeding. With a median follow up of 3 years, the actu-
arial 3-year relapse-free survival was 77% and the cause-specific
survival was 94%. Of the 16 patients who relapsed, 12 were
successfully salvaged with combination chemotherapy leading to
an overall level of survival equivalent to that obtained with initial
cisplatin-based combination chemotherapy. These results were
supported by early results of phase II studies of single agent carbo-
platin from Germany (Dieckmann et al, 1990; Schmoll et al, 1991)
and formed the basis of the decision to launch a trial to compare
progression-free survival after either carboplatin or the com-
bination of etoposide, cisplatin. It was anticipated that 250 
patients should be recruited in order to exclude a 15% reduction in
progression-free survival. However, following recruitment of 125
patients, the trial was closed on the advice of an independent data
monitoring committee on the basis of results of carboplatin in 
non-seminoma, slowing recruitment and a trend towards inferior
results on the carboplatin arm. The trial was thus under-powered 
to determine the possibility of significant differences in major
survival endpoints between the two arms and though the
progression-free survival at 3 years was 10% lower after single
agent carboplatin, the 95% confidence intervals on the difference
is –6% to +19%. As a consequence of salvage treatment, the
difference in overall survival was even less at 5% in favour of EP
but with 95% confidence intervals ranging from –20% to +10%. 
No other randomized trials focusing solely on seminoma have
yet been reported fully, although a German trial of single agent
carboplatin versus etoposide ifosfamide cisplatin has been
reported in abstract (Clemm et al, 2000), to show inferior disease
control by single agent carboplatin, but no difference in overall
survival. Seminoma patients have often been included with good
prognosis non-seminoma for the purposes of randomized trials
(Einhorn et al, 1989; Bajorin et al, 1993; Loehrer et al, 1995) 
but rarely in sufficient numbers to permit meaningful treatment
comparisons. The most useful randomized data comes from the
randomized trial of etoposide/cisplatin (EP) versus etoposide/
carboplatin (EC) in good prognosis metastatic germ cell tumours
(Bajorin et al, 1993). This trial included 64 patients with his-
tologically pure seminoma and normal AFP. 27 of 31 patients
randomized to EP achieved a complete response, with 2 of the 
4 who failed to do so suffering early death. No relapses occurred
with a median follow-up of 22 months, and so a durable response
rate of 87% was reported. Of 33 patients allocated EC, 2 failed 
to achieve a complete response and 4 patients (13%) relapsed
following a complete response. The durable response rate was
therefore 82%. These regimens included Etoposide at 100 mg per
m2 per day for 5 days, a higher dose than in our trial; the outcomes
were similar but small numbers and the risk of selection has
precluded a conclusion on optimal etoposide dose. 
A retrospective analysis was performed on 143 patients with
advanced seminoma treated at the Memorial Sloan Kettering Can-
cer Center (MSKCC) (Mencel et al, 1994). In a non-randomized
comparison, durable response rates of 79% were reported for the
43 patients treated with the VAB-6 regimen, 92% in 60 patients
treated with EP, and 83% in 35 patients treated with EC. Again 
in a non-randomized comparison, 3-year progression-free survival
rates were reported by the MRC (Fosså et al, 1997) in a publication
reporting prognostic factors in metastatic seminoma. The database
Carboplatin chemotherapy in advanced seminoma 1627
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Figure 1 Progression-free survival by allocated treatment. 3 year % PFS
(95% CI) are for C, 71 (60–82); for EP 81 (71–90). Log rank P = 0.21 
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Figure 2 Overall survival by allocated treatment. 3 year % S (95% CI) are
for C 84 (75–92); for EP 89 (81–96). Log rank P = 0.73included 58 patients treated with C, with a 3-year PFS 
of 79%, 15 treated with single agent cisplatin with 100% 3-year
PFS, and 69 patients treated with BEP, in whom the 3-year PFS
was 88%. As with the MSKCC study, patient characteristics 
were not reported separately for each treatment group, and so the
confounding influence of an imbalance in such factors cannot
readily be assessed. 
Our protocol did not specify a requirement for treatment of any
residual masses immediately following chemotherapy since these
are particularly common after treatment of bulky seminomatous
masses and usually do not contain persisting malignancy (Horwich
and Dearnaley, 1992). There is little evidence for routine adjuvant
treatment after combination chemotherapy (Schultz et al, 1989;
Duchesne et al, 1997). It has been suggested that residual 
masses more than 3 cm in diameter early in the period following
chemotherapy may be at greater risk of containing viable semi-
noma (Motzer et al, 1988; Puc et al, 1996) and the protocol there-
fore recommended a biopsy of any residual mass more than 5 cm
in diameter. In this trial, only 5 residual masses in 4 patients in this
time period were resected (1) or biopsied (3) and one revealed
viable seminoma. 96 patients had residual masses of whom 89
were managed by observation; a detailed failure analysis of these
patients is the subject of a separate analysis and report. 
The efficacy of carboplatin noted in phase II studies of the treat-
ment of advanced seminoma has led to its evaluation in the role of
adjuvant therapy post-orchidectomy in stage I seminoma as an
alternative to retroperitoneal lymph node irradiation (Oliver et al,
1994). Oliver and colleagues found that of 54 patients with stage I
seminoma treated with 2 cycles of adjuvant carboplatin, there were
2 recurrences after a median follow up of 62 months and of 65
patients with stage I seminoma, treated with a single cycle of adjuv-
ant carboplatin, there were no recurrences after a median follow up
of 20 months. This has led to a current trial coordinated through
the UK Medical Research Council (TE19) to evaluate carboplatin
in the adjuvant treatment of stage I seminoma by prospective
randomized comparison with adjuvant radiotherapy. 
Current levels of evidence do not provide a sufficiently secure
basis to recommend single agent carboplatin for the chemotherapy
of advanced metastatic seminoma. The PFS we found after carbo-
platin of 71% at 3 years, was not significantly different from the
81% found after EP, and more patients relapsing after carboplatin
were salvaged (12/19 compared to 5/14) leading to very similar
levels of mortality (7 or 8 after carboplatin; 8 after EP) from
progressive GCT. The lack of significant differences in outcomes
in this trial comparing single agent carboplatin with etoposide and
cisplatin may be a consequence of the low power of the trial to
determine clinically important differences between the treatments.
The ongoing trial from the German Testicular Cancer Group,
comparing single agent carboplatin with the combination of etopo-
side, ifosphamide and cisplatin will contribute to this judgement.
A recent prognostic factor analysis based on 236 patients with
advanced seminoma treated with cisplatin-based chemotherapy at
10 European Oncology Units (Fosså et al, 1997) identified a good
prognosis group comprising patients who had not been treated
previously with radiotherapy, and who had either stage II semi-
noma with any serum lactate dehydrogenase (LDH) level at
presentation or stage III and IV patients without non-pulmonary
visceral metastases whose serum LDH was less than 2 × the upper
limit of normal. These patients had a 94% 3-year progression-free
survival (PFS). The poor prognostic group included all other
patients and had a 56% 3-year progression-free survival (Fosså 
et al, 1997). 
Our results are consistent with this classification. In the 94
patients who could be classified, 86 would be in the good prog-
nosis group and had a 3-year PFS probability of 84% (95% CI,
80–88%) and 8 would be in the poor prognosis group with a 3-year
PFS probability of 44% (95% CI, 8–80%). 
The International Germ Cell Cancer Collaborative Group
(IGCCCG) classification of prognosis in metastatic seminoma
(International Germ Cell Cancer Collaborative Group, 1997)
identified a good prognosis group without non-pulmonary visceral
metastases with a 5-year PFS rate of 82% and an ‘intermediate
prognosis’ group, who did have non-pulmonary visceral metas-
tases, with a 5-year PFS rate of 67%. On this classification patients
in our trial with good prognosis (n = 125) had a 77% PFS at 
3 years (95% CI, 69–84%) and those 5 with intermediate prog-
nosis had a 3-year PFS rate of 60% (95% CI, 20–99%). 
A reasonable recommendation for standard practice would be to
treat a good prognosis group with the combination of etoposide
and cisplatin, and to regard carboplatin as a reasonable alternat-
ive for those few patients unable to tolerate cisplatin due to co-
morbid disease. For the small number of patients who present with
poor risk factors more intensive treatment using bleomycin or an
alternative agent in combination with EP or entry into appropriate
phase III studies which include NSGCT patients would be
appropriate. 
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